Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) have been assigned an average rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $77.00.
A number of analysts have commented on BTAI shares. Canaccord Genuity Group lowered their target price on shares of BioXcel Therapeutics from $95.00 to $81.00 in a report on Friday, March 11th. HC Wainwright lifted their price objective on BioXcel Therapeutics from $130.00 to $134.00 and gave the stock a “buy” rating in a research note on Thursday, April 14th. UBS Group dropped their price objective on BioXcel Therapeutics from $88.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, February 16th. Finally, Bank of America raised their target price on BioXcel Therapeutics from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, April 6th.
Shares of BTAI stock opened at $13.11 on Monday. The firm has a market cap of $366.82 million, a price-to-earnings ratio of -3.21 and a beta of 1.05. BioXcel Therapeutics has a 12 month low of $12.33 and a 12 month high of $39.00. The stock has a 50-day moving average price of $17.26 and a 200 day moving average price of $20.89.
Institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its position in shares of BioXcel Therapeutics by 391.5% during the 2nd quarter. Morgan Stanley now owns 119,262 shares of the company’s stock worth $3,466,000 after purchasing an additional 94,997 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of BioXcel Therapeutics in the third quarter worth $207,000. Raymond James & Associates raised its stake in BioXcel Therapeutics by 12.1% in the third quarter. Raymond James & Associates now owns 8,127 shares of the company’s stock valued at $247,000 after purchasing an additional 874 shares in the last quarter. Deutsche Bank AG lifted its position in BioXcel Therapeutics by 35.8% during the third quarter. Deutsche Bank AG now owns 32,894 shares of the company’s stock worth $999,000 after purchasing an additional 8,670 shares during the period. Finally, Advisor Group Holdings Inc. grew its stake in BioXcel Therapeutics by 9.6% during the third quarter. Advisor Group Holdings Inc. now owns 15,322 shares of the company’s stock worth $465,000 after buying an additional 1,337 shares in the last quarter. Institutional investors own 49.77% of the company’s stock.
BioXcel Therapeutics Company Profile (Get Rating)
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.